Last reviewed · How we verify
CB-103
At a glance
| Generic name | CB-103 |
|---|---|
| Also known as | Cellestia, Letrozole, Anastrozole |
| Sponsor | Glenn J. Hanna |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- diarrhoea
- fatigue
- dyschromatopsia
- anaemia
- vision blurred
- dyspepsia
- vomiting
Key clinical trials
- Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL (PHASE2)
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (PHASE1, PHASE2)
- Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies (PHASE1, PHASE2)
- CB-103 Plus NSAI In Luminal Advanced Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-103 CI brief — competitive landscape report
- CB-103 updates RSS · CI watch RSS
- Glenn J. Hanna portfolio CI